# The effect of centralized care on the management of postoperative fluctuations in plasma sodium concentration after pediatric suprasellar brain tumor surgery

**Authors:** S. C. Hulsmann, D. C. Zaal, J.P.J. van Gestel, M. Sie, O.H.J. Eelkman Rooda, K.M. van Baarsen, R.E.A. Musson, B. Bakker, E.E.S. Nieuwenhuis, E.W. Hoving, R.M. Wösten-van Asperen, H. M. van Santen

PMC · DOI: 10.1007/s11102-026-01666-w · 2026-03-29

## TL;DR

Centralizing pediatric brain tumor care in the Netherlands reduced dangerous sodium fluctuations after surgery, possibly due to better management of a hormone deficiency.

## Contribution

This study shows that centralizing care improved postoperative sodium management in children with brain tumors.

## Key findings

- Postoperative AVP-D occurred in 69.7% of patients, but sodium fluctuations were less severe after centralization.
- Sodium fluctuations ≥10 mmol/L/24h decreased from 75.3% pre-centralization to 49.1% post-centralization.
- Maximum sodium delta dropped from 46 mmol/L/24h pre-centralization to 14 mmol/L/24h in 2023.

## Abstract

Children undergoing neurosurgery for (supra)sellar tumors are at risk of developing arginine vasopressin-deficiency (AVP-D), which can cause severe sodium fluctuations and associated neurological complications, prolonged hospitalization and mortality. A previous Dutch study reported sodium shifts ≥ 10 mmol/L/24 h in 75.3% of patients with early postoperative AVP-D, with a maximum delta of 46 mmol/L/24 h. Since 2018, pediatric oncology care has been centralized in the Netherlands. We evaluated the impact of this centralization on postoperative sodium fluctuations in children with (supra)sellar tumors.

Data from all children who underwent neurosurgery for a (supra)sellar tumor at the Princess Máxima Centrum (Utrecht, the Netherlands) between January 2018 and December 2023 were retrospectively collected from electronic health records, including presence of preoperative AVP-D, plasma sodium concentrations during the first 10 postoperative days, administration of desmopressin, and short- and long-term neurological symptoms. Results were additionally interpreted in the context of pre-centralization data.

Among 73 patients with a median age of 7.9 years (range 0-17.5) at tumor resection, postoperative AVP-D occurred in 69.7%. During the first 10 postoperative days, sodium fluctuations ≥ 10 mmol/L/24 h were seen in 49.1% of these patients, with a maximum delta of 30 mmol/L/24 h. Since 2018, sodium fluctuations diminished, with a maximum delta plasma sodium of 14 mmol/L/24 h in 2023. No association was found between early postoperative AVP-D and occurrence of neurological symptoms.

Trends observed after centralization of care for children with (supra)sellar tumors may suggest improved postoperative AVP-D management, resulting in less frequent and less severe fluctuations in plasma sodium concentrations.

The online version contains supplementary material available at 10.1007/s11102-026-01666-w.

## Linked entities

- **Diseases:** arginine vasopressin-deficiency (MONDO:0007450)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** AVP (arginine vasopressin) [NCBI Gene 551] {aka ADH, ARVP, AVP-NPII, AVRP, VP}
- **Diseases:** hypernatremia (MESH:D006955), germinoma (MESH:D018237), Coma (MESH:D003128), SIADH (MESH:D007177), hypothalamus-pituitary axes deficient (MESH:D007029), GH deficiency (MESH:D004393), seizures (MESH:D012640), Hyponatremia (MESH:D007010), motor deficit (MESH:D009461), brain tumor (MESH:D001932), cerebral edema (MESH:D001929), fatigue (MESH:D005221), oliguria (MESH:D009846), craniopharyngioma (MESH:D003397), DI (MESH:D003919), encephalopathy (MESH:D001927), polyuria (MESH:D011141), intracranial pressure (MESH:D019586), hydrocephalus (MESH:D006849), visual impairment (MESH:D014786), CPP (MESH:D020288), ACTH deficiency (MESH:C562707), (supra)sellar tumor (MESH:D009369), central precocious puberty (MESH:D011629), myelinolysis (MESH:D017590), Pituitary adenoma (MESH:D010911), glioma (MESH:D005910), dehydration (MESH:D003681), sleepiness (MESH:D000077260), headache (MESH:D006261), central hypogonadism (MESH:D007006), endocrine disorders (MESH:D004700), neurological sequelae (MESH:D009422), Pituitary dysfunction (MESH:D010900), sellar or suprasellar tumor (MESH:D020863), neurological complications (MESH:D002493), AVP-D (MESH:D020790), acute (MESH:D000208), cognitive dysfunction (MESH:D003072), sleeping problems (MESH:D012893), pilocytic astrocytoma (MESH:D001254), epileptic seizures (MESH:D004827), ODS (MESH:D003711), Mortality (MESH:D003643), hypothyroidism (MESH:D007037), hamartoma (MESH:D006222), Obesity (MESH:D009765), hypotension (MESH:D007022), hypopituitarism (MESH:D007018), Panhypopituitarism (MESH:C563172), rhabdomyosarcoma (MESH:D012208)
- **Chemicals:** water (MESH:D014867), steroids (MESH:D013256), sodium (MESH:D012964), D (MESH:D003903), vincristine (MESH:D014750)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13033463/full.md

---
Source: https://tomesphere.com/paper/PMC13033463